These findings are corroborated by recent report that the expression of key components of the SUMO-involved regulatory network including enhanced UBE2I and SAE1 gene expression levels were strongly linked to poor prognosis in HCC [23] and that the SUMOylation pathway is associated with adverse clinical outcome for patients with multiple myeloma [24]. Here, UBE2I is linked to hepatocellular carcinoma.